L-Pyroglutamic acid

CAS No. 98-79-3

L-Pyroglutamic acid( Pidolic acid | EINECS 202-700-3 | Glutimic acid | NSC143034 | NSC 9966 | NSC-9966 )

Catalog No. M16901 CAS No. 98-79-3

A cyclized derivative of l-glutamic acid. Elevated blood levels may be associated with problems of glutamine or glutathione metabolism.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    L-Pyroglutamic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    A cyclized derivative of l-glutamic acid. Elevated blood levels may be associated with problems of glutamine or glutathione metabolism.
  • Description
    A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of glutamine or glutathione.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Pidolic acid | EINECS 202-700-3 | Glutimic acid | NSC143034 | NSC 9966 | NSC-9966
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Unusual Amino Acids
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    98-79-3
  • Formula Weight
    129.11
  • Molecular Formula
    C5H7NO3
  • Purity
    >98% (HPLC)
  • Solubility
    soluble in Water
  • SMILES
    O=C(O)[C@H](CC1)NC1=O
  • Chemical Name
    (S)-5-oxopyrrolidine-2-carboxylic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Imming P, et al. Nat Rev Drug Discov. 2006 Oct; 5(10):821-34.
molnova catalog
related products
  • Pyronaridine

    Pyronaridine also known as Malaridine is an antimalarial drug.It inhibits the growth of P. falciparum during the asexual stage and early gametocyte stages (I and II) with an IC50 value of approximately 10 nM.

  • CGP 52432

    CGP52432 is a very potent antagonist of GABAB receptors (IC50 = 85 nM).

  • Epiaschantin

    (+)-Epiaschantin shows marginal cancer cell line inhibitory activities. It also has anti-platelet aggregation activity.